1. Home
  2. About Us
  3. Divisions / Centres / Units
  4. Haematology Medical Oncology and Haemopoietic Stem Cell Transplantation HSCT
  5. Publications

Publications

Introduction Staff list Research Publications Education Clinical service
  • Gill H, Ip HW, Yim R, Tang WF, Pang HH, Lee P, Leung GMK, Li J, Tang K, So JCC, Leung RYY, Li J, Panagioutou G, Lam CCK, Kwong YL. Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis. Ann. Hematol. 2019; 98(4): 869-879
  • Gill H, Kumana CR, Yim R, Hwang YY, Chan TS, Yip SF, Lee HK, Mak V, Lau JS, Chan CC, Kho B. Oral arsenic trioxide incorporation into frontline treatment with all‐trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5‐year prospective study. Cancer. 2019 May 15. [Epub]
  • Gill H, Yim R, Lee HKK, Mak V, Lin SY, Kho B, Yip SF, Lau JSM, Li W, Ip HW, Hwang YY, Chan TSY, Tse E, Au WY, Kumana CR, Kwong YL. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study. Cancer. 2018; 124 (11): 2316-2326
  • Kwong YL, Kim SJ, Tse E, Oh SY, Kwak JY, Eom HS, Do YR, Mun YC, Lee SR, Shin HJ, Suh C, Chuang SS, Lee YS, Lim ST, Izutsu K, Suzuki R, Relander T, d'Amore F, Schmitz N, Jaccard A, Kim WS. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. Ann Oncol. 29(1):256-263, 2018
  • Zhou Y, Wang H, Tse E, Li H, Sun H.  Cell cycle–dependent uptake and cytotoxicity of arsenic-based drugs in single leukemia cells. Anal Chem. 90(17):10465-10471, 2018.
  • Cheng CW, Leong KW, Ng YM, Kwong YL, Tse E. The peptidyl-prolyl isomerase PIN1 relieves cyclin-dependent kinase 2 (CDK2) inhibition by the CDK inhibitor p27. J Biol Chem. 292(52):21431-21441, 2017
  • Chim CS, Kumar S, Orlowski R, Cook G, Richardson PG, Gertz M, Giralt S, Marivi Mateos, Leleu X, Anderson KC. Management of relapsed & refractory multiple myeloma – novel agents, antibodies, immunotherapies and beyond. Leukemia, 2017, in press. (Invited review)(IF: 11.702)
  • Chim CS. LDH as a prognostic marker in AL amyloidosis: expected or unexpected? (Invited editorial) Br J Haematol, 2017 Sep; 178(6):833-835. (IF: 5.67)
  • Kwong YL, Chan TS, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung, R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed and refractory NK/T-cell lymphoma failing L-asparaginase. Blood. 129(17):2437-2442, 2017.
  • Leong KW, Cheng CW, Wong CM, Ng IO, Kwong YL, Tse E. miR-874-3p is downregulated in hepatocellular carcinoma and negatively regulates PIN1 expression. Oncotarget. 8(7):11343-11355, 2017.
  • Piao WY, Chau D, Yue LM, Kwong YL, Tse E. Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma. Leukemia. 31(2):522-6, 2017.
  • Reddy A, ……, Tse E, ……, Dave SS. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell. 171(2):481-94, 2017.
  • Tse E and Kwong YL. How I Treat NK/T-cell Lymphoma. Blood. 121(25):4997-5005, 2013.
  • Yinlei Bai, Alberto Orfao, Chor Sang Chim. Molecular Detection of Minimal Residual Disease in Multiple Myeloma. British Journal of Haematology, 2017, in press. (Invited review) (IF: 5.67)
  • Gill H, Leung AY, Chan CC, Lau JS, Chan C, Yip SF, Liu H, Koh B, Mak V, Lin SY, Lau CK, Kwong YL. Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis. Hematology. 2016; 21(1): 10-18
  • Gill H, Leung AY, Kwong YL. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy. Int J Mol Sci. 2016; 17(4): 440.
  • Lam SS, Ho ES, He BL, Wong WW, Cher CY, Ng NK, Man CH, Gill H, Cheung AM, Ip HW, So CC, Tamburini J, So CW, Ho DN, Au CH, Chan TL, Ma ES, Liang R, Kwong YL, Leung AY. Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia. Sci Transl Med 2016; 8(359): 359ra129.
  • LQ Wang, KY Wong, ZH Li, CS Chim. Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia. Oncotarget, 2016; 7(50):82400-82410. (IF: 5.168)
  • Yinlei Bai, KY Wong, TK Fung, CS Chim. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes. Journal of Hematology & Oncology, 2016; 9: 107. (IF: 6.350)
  • Chau D, Ng K, Chan TS, Cheng YY, Fong B, Tam S, Kwong YL, Tse E. Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by upregulating the arsenic transporter aquaglyceroporin 9. J Hematol Oncol. 8(1):46, 2015.
  • Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28: 269-77.(IF: 11.702)
  • Gill H, Leung AY, Kwong YL. Molecularly targeted therapy in acute myeloid leukemia. Future Oncol. 2015; 12(6): 826-38
  • Gill H, Man CH, Ip AH, Choi WW, Chow HC, Kwong YL, Leung AY. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia. Haematologica 2015; 100(7): e250-3.
  • Lu Qian Wang, Kwan Yeung Wong, Anders Rosèn and Chor Sang Chim. Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways. Oncotarget. 2015; 6(42):44422-36. (IF: 5.168)
  • Man CH, Fung TK, Wan H, Cher CY, Fan A, Ng N, Ho C, Wan TS, Tanaka T, So EC, Kwong YL, Leung AY. Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia. Blood. 2015;125(25):3928-36
  • Meletios Athanasios Dimopoulos, Jens Hillengass, Saad Usmani, Elena Zamagni, Suzanne Lentzsch, Faith Davies, Noopur Raje, Orhan Sezer, Sonja Zweegman, Jatin Shah, Ashraf Badros, Kazuyuki Shimizu, Philippe Moreau, Chor-Sang Chim, Juan Jose Lahuerta, Jian Hou, Artur Jurczyszyn, Hartmut Goldschmidt, Pieter Sonneveld, Antonio Palumbo, Heinz Ludwig, Michele Cavo, Bart Barlogie, Kenneth C Anderson, G David Roodman, S. Vincent Rajkumar, Brian Durie, and Evangelos Terpos. The Role of Magnetic Resonance Imaging in the Management of Patients with Multiple Myeloma: a Consensus Statement on behalf of the International Myeloma Working Group. J Clin Oncol, 2015 Feb 20;33(6):657-64. (IF: 24.008)
  • Shi X, He BL, Ma AC, Guo Y, Chi Y, Man CH, Zhang W, Zhang Y, Wen Z, Cheng T, Leung AY. Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish. Blood. 2015;125(19):2974-84.
  • Tse E, Kwong YL. T-cell lymphoma: microenvironment-related biomarkers. Semin Cancer Biol. 34:46-51, 2015.
  • Chi-lai Ho, S Chen, YL Leung, T Cheng, Ka-nin Wong, SK Cheung, R Liang, C S Chim. 11C-Acetate for Metabolic Characterization of Multiple Myeloma – A Comparative PET/CT Study with 18F-Fluorodeoxyglucose PET/CT. Journal of Nuclear Medicine, 2014 May;55(5):749-52 (IF: 6.646)
  • Gill H, Au WY, Cheung WW, Kwong YL. Oral arsenic trioxide based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma. Ann. Oncol. 2014; 25 (7): 1391-7
  • He BL, Shi X, Man CH, Ma AC, Ekker SC, Chow HC, So CW, Choi WW, Zhang W, Zhang Y, Leung AY*. Functions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia. Blood. 2014;123(16):2518-29.
  • Man CH, Lam SS, Sun MK, Chow HC, Gill H, Kwong YL, Leung AY*. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML. Blood. 2014;123(16):2530-9.
  • RLH YIM, KY WONG, YL KWONG, Florence LOONG, CY LEUNG, Raymond CHU, WW LAM, PK HUI, Raymond LAI, CS CHIM. Methylation of miR-155-3p in mantle cell and other non-Hodgkin's lymphoma. Oncotarget, 2014; 5: 9770-82 (IF: 5.168)
  • Cheng CW, Chow AK, Pang R, Fok EW, Kwong YL and Tse E. PIN1 inhibits apoptosis in hepatocellular carcinoma through modulation of the anti-apoptotic function of survivin. Am J Pathol. 182(3):765-75, 2013.
  • Kwong YL, Pang AW, Leung AY, Chim CS, Tse E. Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia 2013 Jul 11. [Epub ahead of print] (Impact factor: 10.164)
  • Wang LQ, Kwong YL, Kho CS, Wong KF, Wong KY, Ferracin M, Calin GA, Chim CS. Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFκB pathway. Mol Cancer. 2013;12:173. (IF: 6.204)
  • Wong KY, Yim RL, Kwong YL, Leung CY, Hui PK, Cheung F, Liang R, Jin DY, Chim CS. Epigenetic inactivation of the MIR129-2 in hematological malignancies. J Hematol Oncol. 2013; 6:16. (IF: 6.350)
  • Chim CS, Lie AK, Chan EY, Liu HS, Lau CW, Yip SF, Sim J, Wan TS, Ma ES, Liang R, Tse E, Kwong YL; Hong Kong Society of Myeloma. Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD. J Hematol Oncol. 2012;5:28. (IF: 6.350)
  • Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012;120(15):2973-80. (Impact factor: 9.060)
  • Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Cheung AM, Eaves CJ, Kwong YL, Leung AY*.  Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness with the emergence of a D835 mutation.  Blood 2012; 119(22): 5133-43.
  • Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Lok S, Cheung AM, Eaves C, Kwong YL, Leung AY. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood 2012;119(22):5133-43. (Impact factor: 9.060)
  • Wong KY, Huang X, Chim CS. DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis. 2012 Sep;33(9):1629-38. (IF: 5.105)
  • Yim RL, Kwong YL, Wong KY, Chim CS. DNA Methylation of Tumor Suppressive miRNAs in Non-Hodgkin's Lymphomas. Front Genet. 2012 Nov 8;3:233.
  • Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, Lau JS, Kwong YL. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood 2011;118(25):6535-43. (Impact factor: 9.060)
  • Kwan-Yeung Wong, Raymond Liang, Chi-Chiu So, Yanting Qi, Dong-Yan Jin, Joseph F. Costello, Chim CS. Epigenetic silencing of miR-203 in multiple myeloma. Br J Haematol, 2011 Sep; 154(5): 569-78. (IF: 5.67)
  • KY Wong, Rita LH Yim, CC So, DY Jin, Raymond Liang, Chim CS. Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood 2011; 118: 5901-5904 (IF: 13.164).
  • Ma AC, Fung TK, Lin RH, Chung MI, Yang D, Ekker SC, Leung AY*.  Methionine aminopeptidase 2 is required for hematopoietic stem cell initiation and proliferation.  Blood 2011; 118(20):5448-57. 
  • Wong KY, Yu L, Chim CS. DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics. 2011 Feb;3(1):83-92. (IF: 4.541)
  • Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011;29(33):4410-6. (Impact factor: 18.038)
  • Chim CS, KY Wong, Y Qi, Loong F, WL Lam, LG Wong, Jin DY, Costello JF, Liang R. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis, 2010, 31(4):745-50 (Impact Factor: 5.105).
  • Ma AC, Chung MI, Liang R, Leung AY*. A DEAB-sensitive aldehyde dehydrogenase regulates hematopoietic stem and progenitor cells development during primitive hematopoiesis in zebrafish embryos. Leukemia. 2010; 24(12):2090-9.
  • Ma AC, Chung MI, Liang R, Leung AY*. The role of survivin2 in primitive hematopoiesis during zebrafish development. Leukemia. 2009;23(4):712-20.
  • Au WY, Tam S, Fong BM, Kwong YL. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood 2008;112(9):3587-90. (Impact factor: 9.060)
  • Chim CS, Pang R, Fung TK, Choi CL, Liang R. Epigenetic Dysregulation of Wnt Signaling Pathway in Multiple Myeloma. Leukemia; 21(12): 2527-36, 2007. (IF: 11.702)
  • Leung J, Pang A, Yuen WH, Kwong YL, Tse EW. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood 2007;109(2):740-6. (Impact factor: 9.060)
  • Ma AC, Ward AC, Liang R, Leung AY*.  The role of Jak2a in zebrafish hematopoiesis.  Blood 2007;110(6):1824-30. 
  • Pang R, Lee TKW, Poon RT, Fan ST, Wong KB, Kwong YL and Tse E. Pin1 interacts with a specific serine-proline motif of hepatitis B virus x-protein to enhance hepatocarcinogenesis. Gastroenterology. 132(3):1088-103, 2007.
  • Wong AS, Chan KH, Cheng VC, Yuen KY, Kwong YL, Leung AY. Relationship of pretransplantation polyoma BK virus serologic findings and BK viral reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 2007;44(6):830-7. (Impact factor: 9.374)
  • Au WY, Tam S, Fong BM, Kwong YL. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia. Blood 2006;107(7):3012-3. (Impact factor: 9.060)
  • Siu CW, Au WY, Yung C, Kumana CR, Lau CP, Kwong YL, Tse HF. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood 2006;108(1):103-6. (Impact factor: 9.060)
  • Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK, Lam CC, Leung AY, Tse E, Yau CC, Liang R, Kwong YL. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005;16(2):206-14. (Impact factor: 7.384)
  • Au WY, Pang A, Chan EC, Chu KM, Shek TW, Kwong YL. Epstein-barr virus-related gastric adenocarcinoma: an early secondary cancer post hemopoietic stem cell transplantation. Gastroenterology 2005;129(6):2058-63. (Impact factor: 12.821)
  • Chim CS, Kwong YL, Lie AK, Ma SK, Chan CC, Wong LG, Kho BC, Lee HK, Sim JP, Chan CH, Chan JC, Yeung YM, Law M, Liang R. Long-term outcome of 231 patients with Essential Thrombocythemia: Prognostic factors for bleeding, thrombosis, myelofibrosis and leukaemia. JAMA Internal Medicine (previously Archives Int Med), 2005, 165: 2651-2658. (IF:16.538)
  • Chim CS, Wong SY, Pang A, Chu P, Lau JS, Wong KF, Kwong YL. Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute promyelocytic leukemia. Leukemia. 2005; 19(12): 2241-6 (IF: 11.702).
  • Leung AY, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL, Liang R, Lie AK, Kwong YL. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2005;40(4):528-37. (Impact factor: 9.374)
  • Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004;104(1):243-9. (Impact factor: 9.060)
  • Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 Hypermethylation in Multiple Myeloma: Implications for Epigenetic Activation of the Jak/STAT pathway. Blood 2004; 103: 4630-4635. (IF: 13.164).
  • Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, Yau CC, Kwong YL. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004, 103: 216-221 (IF: 13.164).
  • Pang R, Yuen J, Yuen MF, Lai CL, Lee TK, Man K, Poon RT, Fan ST, Wong CM, Ng IO, Kwong YL and Tse E. PIN1 over-expression and β-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 23(23): 4182-6, 2004.
  • Au WY, Kumana CR, Kou M, Mak R, Chan GC, Lam CW, Kwong YL. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 2003;102(1):407-8. (Impact factor: 9.060)
  • Au WY, Lie AK, Chim CS, Liang R, Ma SK, Chan CH, Mak YK, Chen YT, So CC, Yeung YM, Yip SF, Wong LG, Chan JC, Liu SY, Kwong YL. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. Ann Oncol 2003;14(5):752-7. (Impact factor: 7.384)
  • Tse E, Chung G and Rabbitts TH. Isolation of Antigen-Specific Intracellular Antibody Fragments as Single Chain Fv for Use in Mammalian Cells. In Methods in Molecular Biology: Embryonic Stem Cells: Methods and Protocols. Edited by K.Turksen. vol. 185: p433-446, 2002 (Eds. Turksen K) Humana Press Inc., Totowa, NJ
  • Tse E, Lobato MN, Forster A, Tanaka T, Chung GT and Rabbitts TH. Intracellular Antibody Capture Technology: Application to selection of intracellular antibodies recognizing the BCR-ABL oncogenic protein. J. Mol. Biol. 317(1): 85-94, 2002.
  • Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 2004;103(12):4630-5. (Impact factor: 9.060)
  • Chim CS, Liang R, Tam CY, Kwong YL. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J Clin Oncol, 19: 2033-2040, 2001. (IF: 24.008)
  • Leung AY, Suen CK, Lie AK, Liang RH, Yuen KY, Kwong YL. Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood 2001;98(6):1971-8. (Impact factor: 9.060)
  • Tse E and Rabbitts TH. Intracellular antibody-caspase medicated cell killing: an approach for application in cancer therapy. Pro. Natl. Acad. Sci. USA. 97(22): 12266-71, 2000.
  • Visintin M, Tse E, Axelson H, Rabbitts TH and Cattaneo A. Selection of antibodies for intracellular function using a two-hybrid in vivo system. Pro. Natl. Acad. Sci. USA. 96(21): 11723-8, 1999.
  • Kwong YL, Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 1997;89(9):3487-8. (Impact factor: 9.060)